Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has disclosed a board resolution to convene the 15th Extraordinary General Meeting of Shareholders on October 17, 2025, at Songdo Convensia to vote on the approval of the spin-off plan.
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: Resolution on Convening General Meeting of Shareholders
- Meeting Type: Extraordinary General Meeting of Shareholders (EGM)
- Date & Time: October 17, 2025, at 9:00 AM KST
- Location: Room 113, 1st Floor, Songdo Convensia (123 Central-ro, Yeonsu-gu, Incheon)
- Main Agenda Items:
- Reporting Items: Audit Report
- Voting Items: Agenda Item No. 1 – Approval of Spin-off Plan
- Board Resolution Date: October 02, 2025
- Board Attendance: 4 Outside Directors Present (0 Absent)
- Other Important Details:
- Record Date for Voting Rights: July 29, 2025
- Spin-off Plan Reference: Key Management Matters (Decision on Corporate Spin-off) disclosed on August 22, 2025
- Related Disclosures:
- September 23, 2025: Prospectus
- September 11, 2025: Securities Registration Statement (Spin-off)
- August 22, 2025: Decision on Corporate Spin-off
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verifying EGM Convening and Voting Outcome of the Spin-off Plan Agenda
This disclosure provides notice regarding the schedule for convening an Extraordinary General Meeting of Shareholders to officially decide on the proposed corporate spin-off.
Monitoring the voting results of Agenda Item No. 1 (Approval of Spin-off Plan) on the scheduled meeting date (October 17, 2025) is essential.
Relevant resolution results can be verified in subsequent official disclosures regarding the EGM results.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
